A twice-yearly HIV prevention jab will be available at low cost in 120 lower income countries beginning in 2027.
The drug, known as lenacapavir, has been hailed as a medical breakthrough that could change the trajectory of the global HIV epidemic, which affects about 40.8 million people worldwide.
